Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapirolizumab pegol - Biogen/UCB

Next Previous
X
Search
Drug Profile

Dapirolizumab pegol - Biogen/UCB

Alternative Names: Anti-CD40L Fab; Anti-CD40L Fab-PEG; BIIB 133; CD40L - Fab; CDP-7657; DZP; Peg-dapirolizumab; Pegylated anti-CD40L antibody

Latest Information Update: 01 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec; UCB
  • Developer ALS Therapy Development Institute; Biogen; UCB
  • Class Anti-inflammatories; Antibodies; Antirheumatics; Fab fragments; Polyethylene glycols
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • Discontinued Amyotrophic lateral sclerosis; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 24 Sep 2024 Efficacy and adverse events data from phase-III PHOENYCS GO trial in Systemic lupus erythematosus released by UCB
  • 30 Jul 2024 Discontinued - Phase-II for Multiple sclerosis (Treatment-experienced) in France (IV) prior to July 2024
  • 28 Jun 2024 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top